Anakinra for Steroid Refractory Chimeric Antigen Receptor T-cell Therapy Toxicities

Key Points

• Anakinra significantly decreases cytokine release syndrome severity in patients with CAR T-cell therapy toxicities.
• The treatment showed a reduction in adverse effects, with 60% of patients responding favorably within one month.
• Observational analysis included diverse patient demographics, focusing on those experiencing severe toxicities.
• Further research is needed for external validation and exploration of long-term safety outcomes for these patients.